Skip to content

TYRA BIOSCIENCES, INC.

US · TYRA #3032 by market cap Listed 2021
20.12 +0.39 +1.98%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

About TYRA BIOSCIENCES, INC.

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SN?P, enables the rapid and precise refinement of structural design through iterative molecular SN?Pshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.

Founded
2018
CEO
Dr. Todd Harris, PhD
Employees
87
Headquarters
Carlsbad, California, United States of America
Fiscal year end
12-31
Website
tyra.bio

Company profile

Exchange
US
Symbol
TYRA
Market-cap rank
#3032
Listing date
2021-09-15
Market cap
1.39B
Float cap
810.64M
Shares out
69.08M
Float shares
40.29M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 19:30:00 · For reference only, not investment advice and not tailored to your situation.

TYRA BIOSCIENCES, INC. discussion 0 comments

Add a comment